

Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)

Technology appraisal guidance

Published: 16 July 2026

www.nice.org.uk/guidance/ta1180

Contents

Advice..... 3

 What this means in practice..... 3

Advice

NICE is unable to make a recommendation about the use in the NHS of netarsudil for treating open-angle glaucoma or ocular hypertension in adults. This is because Santen UK & Ireland has confirmed that it does not intend to make an evidence submission for the evaluation. It considers that there is not enough evidence to provide an evidence submission and it will not be launching the technology at this time.

NICE will review the position if the company decides that it wants to make an evidence submission.

What this means in practice

Netarsudil is not required to be funded in the NHS in England for the condition and population stated in this terminated evaluation.

This is because an evidence submission was not provided, so NICE is unable to evaluate whether netarsudil offers benefit and is value for money in this population.

If NHS organisations wish to consider netarsudil for this indication, they should follow the advice on local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). These outline the approach that should be taken when there is no NICE guidance.

ISBN: 978-1-4731-9601-8